Cover Image
市場調查報告書

生物資訊相關的合作契約:合作條件與契約

Global Bioinformatics Partnering Terms and Agreements 2010 to 2016

出版商 Current Partnering, a division of Wildwood Ventures Limited 商品編碼 223199
出版日期 內容資訊 英文 548 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
生物資訊相關的合作契約:合作條件與契約 Global Bioinformatics Partnering Terms and Agreements 2010 to 2016
出版日期: 2016年09月01日 內容資訊: 英文 548 Pages
簡介

本報告提供醫藥品產業的生物資訊相關的各種合作契約動向調查分析,生物資訊相關合作契約的轉變和主要趨勢、大規模契約詳細內容、大型製藥公司的合作契約動向、各開發階段、契約形態、治療領域的契約動向等彙整資料,為您概述為以下內容。

摘要整理

第1章 簡介

第2章 生物資訊相關合約趨勢

  • 簡介
  • 生物資訊合作的轉變
  • 大型醫藥品企業的生物資訊相關合約
  • 大型生物醫藥品企業的生物資訊相關合約
  • 生物資訊相關合約最積極的企業
  • 生物資訊合作:各契約形態
  • 生物資訊合作:各開發階段
  • 生物資訊合作:各疾病類型
  • 生物資訊合作的平均契約條件

第3章 主要生物資訊契約

  • 簡介
  • 主要的生物資訊契約:各契約規模
  • 大型醫藥品企業關聯的主要的生物資訊契約

第4章 大型製藥公司的生物資訊契約

  • 簡介
  • 合作契約的有效利用方法
  • 合作企業簡介(共37家公司)

第5章 大型製藥公司的生物資訊契約

  • 簡介
  • 合作契約的有效利用方法
  • 合作企業簡介(共11家公司)

第6章 生物資訊契約目錄

  • 簡介
  • 各開發階段
    • 藥物研發
    • 製劑
    • 已上市
    • 第三階段
  • 各契約形態
    • 資產購買
    • 大型醫藥品企業的轉出授權
    • 聯合R&D
    • 共同行銷
    • 服務委託
    • 共同促銷
    • 開發
    • 流通
    • 股票買賣
    • 授權
    • 訴訟相關
    • 製造
    • 行銷
    • 選擇
    • 推銷
    • 調查
    • 和解相關
    • 輔助許可證
    • 供給
    • 契約結束
  • 治療領域
    • 心血管
    • 血液
    • 住院照護
    • 感染疾病
    • 腫瘤

第7章 生物資訊契約:各技術種類

  • 生物資訊
  • 軟體工具

第8章 合作:資源中心

  • 線上
  • 活動
  • 相關資料

關於Wildwood Ventures

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: CP2111

The ‘Global Bioinformatics Partnering Terms and Agreements 2010 to 2016’ report provides comprehensive understanding and unprecedented access to the bioinformatics partnering deals and agreements entered into by the worlds leading healthcare companies

The ‘Global Bioinformatics Partnering Terms and Agreements 2010 to 2016’ report provides comprehensive understanding and unprecedented access to the bioinformatics partnering deals and agreements entered into by the worlds leading healthcare companies.

  • Trends in bioinformatics partnering deals
  • Deal terms analysis
  • Partnering agreement structure
  • Partnering contract documents
  • Top deals by value
  • Most active deal makers
  • Financial deal terms for bioinformatics

The Global Bioinformatics Partnering Terms and Agreements 2010 to 2016 report provides comprehensive understanding and unprecedented access to the bioinformatics partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides a detailed understanding and analysis of how and why companies enter bioinformatics partnering deals. The majority of deals are discovery stage whereby the licensee obtains a right or an option right to license the licensors bioinformatics technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

This report provides details of the latest bioinformatics agreements announced in the healthcare sectors.

Bioinformatics is the application of computer science and information technology to the field of biology and medicine. Bioinformatics deals with algorithms, databases, information systems, web technologies, artificial intelligence, information and computation theory, software engineering, data mining, image processing, modeling, simulation, signal processing, discrete mathematics, control systems, and statistics, for generating new knowledge of biology and medicine.

Bioinformatics deals have increased in terms of popularity for partnering in the past decade, as computing power has been embraced in order to speed up the discovery, evaluation and clinical assessment processes.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.

This report contains a comprehensive listing of all bioinformatics partnering deals announced since January 2010, including financial terms where available, including over 800 links to online deal records of actual bioinformatics partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

The initial chapters of this report provide an orientation of bioinformatics dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in bioinformatics dealmaking since 2010, including details of average headline, upfront, milestone and royalty terms.

Chapter 3 provides a review of the leading bioinformatics deals since 2010. Deals are listed by headline value, signed by big pharma, most active bioinformatics dealmaking companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 4 provides a comprehensive listing of the top 25 most active companies in bioinformatics dealmaking with a brief summary followed by a comprehensive listing of bioinformatics deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 5 provides a comprehensive and detailed review of bioinformatics partnering deals signed and announced since Jan to 2010, where a contract document is available in the public domain. The chapter is organized by company A-Z, deal type (collaborative R&D, co-promotion, licensing etc), and specific therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Chapter 7 provides a comprehensive and detailed review of bioinformatics partnering deals signed and announced since Jan to 2010. The chapter is organized by specific bioinformatics technology type in focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In addition, a comprehensive appendix is provided organized by bioinformatics partnering company A-Z, deal type definitions and bioinformatics partnering agreements example. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in bioinformatics partnering and dealmaking since 2010.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of bioinformatics technologies and products.

‘Bioinformatics Partnering Terms and Agreements’ provides the reader with the following key benefits:

  • In-depth understanding of bioinformatics deal trends since 2010
  • Access to headline, upfront, milestone and royalty data
  • Analysis of the structure of bioinformatics agreements with numerous real life case studies
  • Comprehensive access to over 800 bioinformatics deals entered into by the world's biopharma companies
  • Detailed access to actual bioinformatics contracts enter into by the leading fifty bigpharma companies
  • Insight into the terms included in a bioinformatics agreement, together with real world clause examples
  • Understand the key deal terms companies have agreed in previous deals
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Benefits

‘Bioinformatics Partnering Terms and Agreements’ provides the reader with the following key benefits:

  • In-depth understanding of bioinformatics deal trends since 2010
  • Access to headline, upfront, milestone and royalty data
  • Analysis of the structure of bioinformatics agreements with numerous real life case studies
  • Comprehensive access to over 800 bioinformatics deal documents entered into by the world's biopharma companies
  • Detailed access to actual bioinformatics contracts
  • Insight into the terms included in a bioinformatics agreement, together with real world clause examples
  • Understand the key deal terms companies have agreed in previous deals
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in bioinformatics dealmaking

  • 2.1. Introduction
  • 2.2. Bioinformatics partnering over the years
  • 2.3. Most active bioinformatics dealmakers
  • 2.4. Bioinformatics partnering by deal type
  • 2.5. Bioinformatics partnering by therapy area
  • 2.6. Deal terms for bioinformatics partnering
    • 2.6.1. Bioinformatics partnering headline values
    • 2.6.2. Bioinformatics deal upfront payments
    • 2.6.3. Bioinformatics deal milestone payments
    • 2.6.4. Bioinformatics royalty rates

Chapter 3 - Leading bioinformatics deals

  • 3.1. Introduction
  • 3.2. Top bioinformatics deals by value

Chapter 4 - Most active bioinformatics dealmakers

  • 4.1. Introduction
  • 4.2. Most active bioinformatics dealmakers
  • 4.3. Most active bioinformatics partnering company profiles

Chapter 5 - Bioinformatics contracts dealmaking directory

  • 5.1. Introduction
  • 5.2. Bioinformatics contracts dealmaking directory

Chapter 6 - Bioinformatics dealmaking by technology type

Chapter 7 - Partnering resource center

  • 7.1. Online partnering
  • 8.2. Partnering events
  • 8.3. Further reading on dealmaking

Appendices

  • Appendix 1 - Bioinformatics deals by company A-Z
  • Appendix 2 - Bioinformatics deals by stage of development
  • Appendix 3 - Bioinformatics deals by deal type
  • Appendix 4 - Bioinformatics deals by therapy area
  • Appendix 5 -Deal type definitions

About Wildwood Ventures

  • Current Partnering
  • Current Agreements
  • Recent report titles from Current Partnering

Table of figures

  • Figure 1: Bioinformatics partnering since 2010
  • Figure 2: Active bioinformatics dealmaking activity- 2010 to 2016
  • Figure 3: Bioinformatics partnering by deal type since 2010
  • Figure 4: Bioinformatics partnering by disease type since 2010
  • Figure 5: Bioinformatics deals with a headline value
  • Figure 6: Bioinformatics deals with an upfront value
  • Figure 7: Bioinformatics deals with a milestone value
  • Figure 8: Bioinformatics deals with a royalty rate value
  • Figure 9: Top bioinformatics deals by value since 2010
  • Figure 10: Most active bioinformatics dealmakers 2010 to 2016
  • Figure 11: Online partnering resources
  • Figure 12: Forthcoming partnering events
Back to Top